SC 13G/A
1
onvo-13g_20211231.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 2)*
Organovo Holdings, Inc.
----------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $0.001 par value
----------------------------------------------------------------------------
(Title of Class of Securities)
68620A203
----------------------------------------------------------------------------
(CUSIP Number)
December 31, 2021
----------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[X] Rule 13d-1(b)
[_] Rule 13d-1(c)
[_] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities,
and for any subsequent amendment containing information which would alter
the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
=============================================================================
-----------------------------------------------------------------------------
CUSIP NO. 68620A203 13G Page 2 of 8 Pages
-----------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (entities only).
Renaissance Technologies LLC 26-0385758
-----------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):
(a) [_]
(b) [_]
-----------------------------------------------------------------------------
(3) SEC USE ONLY
-----------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF SHARES 137,600
BENEFICIALLY OWNED _____________________________
BY EACH REPORTING
PERSON WITH: (6) SHARED VOTING POWER
0
_____________________________
(7) SOLE DISPOSITIVE POWER
194,287
_____________________________
(8) SHARED DISPOSITIVE POWER
0
______________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
194,287
------------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
------------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.23 %
------------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
IA
Page 2 of 8 pages
=============================================================================
Page 3 of 8 pages
-----------------------------------------------------------------------------
CUSIP NO. 68620A203 13G Page 3 of 8 Pages
-----------------------------------------------------------------------------
(1) NAMES OF REPORTING PERSONS.
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY).
RENAISSANCE TECHNOLOGIES HOLDINGS CORPORATION 13-3127734
-----------------------------------------------------------------------------
(2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
(a) [_]
(b) [_]
-----------------------------------------------------------------------------
(3) SEC USE ONLY
-----------------------------------------------------------------------------
(4) CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
-----------------------------------------------------------------------------
(5) SOLE VOTING POWER
NUMBER OF SHARES 137,600
BENEFICIALLY OWNED _____________________________
BY EACH REPORTING
PERSON WITH: (6) SHARED VOTING POWER
0
_____________________________
(7) SOLE DISPOSITIVE POWER
194,287
_____________________________
(8) SHARED DISPOSITIVE POWER
0
_____________________________
(9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
194,287
-----------------------------------------------------------------------------
(10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(SEE INSTRUCTIONS)
[_]
-----------------------------------------------------------------------------
(11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
2.23 %
-----------------------------------------------------------------------------
(12) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
HC
Page 3 of 8 pages
=============================================================================
-----------------------------------------------------------------------------
CUSIP NO. 68620A203 13G Page 4 of 8 Pages
-----------------------------------------------------------------------------
Item 1.
(a) Name of Issuer
Organovo Holdings, Inc.
(b) Address of Issuer's Principal Executive Offices.
440 Stevens Ave, Suite 200, Solana Beach, CA 92075
Item 2.
(a) Name of Person Filing:
This Schedule 13G is being filed by Renaissance Technologies LLC
("RTC") and Renaissance Technologies Holdings Corporation ("RTHC").
(b) Address of Principal Business Office or, if none, Residence.
The principal business address of the reporting persons is:
800 Third Avenue
New York, New York 10022
(c) Citizenship.
RTC is a Delaware limited liability company, and
RTHC is a Delaware corporation.
(d) Title of Class of Securities.
Common Stock, $0.001 par value
(e) CUSIP Number.
68620A203
Page 4 of 8 pages
=============================================================================
Item 3. If this statement is filed pursuant to Rule 13d-1(b) or 13-d-2(b)
or (c),check whether the person filing is a:
(a) [_] Broker or dealer registered under section 15 of the Act.
(b) [_] Bank as defined in section 3(a)(6) of the Act.
(c) [_] Insurance Company as defined in section 3(a)(19) of the Act.
(d) [_] Investment Company registered under section 8 of the Investment
Company Act.
(e) [x] Investment Adviser in accordance with Sec.240.13d-1(b)(1)(ii)(E).
(f) [_] Employee Benefit Plan or Endowment Fund in accordance with
Sec. 240.13d-1(b)(1)(ii)(F).
(g) [_] Parent holding company, in accordance with Sec.240.13d-1(b)(1)(ii)(G).
(h) [_] A savings associations as defined in Section 3(b) of the Federal
Deposit Insurance Act.
(i) [_] A church plan that is excluded from the definition of an investment
company under section 3(c)(14) of the Investment Company Act of 1940.
(j) [_] Group, in accordance with Sec.240.13d-1(b)(1)(ii)(J).
Item 4. Ownership.
(a) Amount beneficially owned.
RTC: 194,287 shares
RTHC: 194,287 shares, comprising the shares beneficially owned
by RTHC, because of RTHC's majority ownership of RTC.
(b) Percent of Class.
RTC: 2.23 %
RTHC: 2.23 %
(c) Number of shares as to which the person has:
(i) sole power to vote or to direct the vote:
RTC: 137,600
RTHC: 137,600
(ii) Shared power to vote or to direct the vote: 0
(iii) sole power to dispose or to direct the disposition of:
RTC: 194,287
RTHC: 194,287
(iv) Shared power to dispose or to direct the disposition of:
RTC: 0
RTHC: 0
Page 5 of 8 pages
=============================================================================
Item 5. Ownership of Five Percent or Less of a Class.
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than five percent of the class of securities,
check the following: [X]
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
Certain funds and accounts managed by RTC have the right to receive
dividends and proceeds from the sale of the securities which are
the subject of this report.
Item 7. Identification and Classification of the Subsidiary Which Acquired
the Security Being Reported on by the Parent Holding Company.
Not applicable
Item 8. Identification and Classification of Members of the Group.
Not applicable
Item 9. Notice of Dissolution of a Group.
Not applicable
Page 6 of 8 pages
=============================================================================
Item 10. Certification
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and not acquired and are not held for the purpose of or
with the effect of changing or influencing the control of the issuer of the
securities and were not acquired and are not held in connection with or as
a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
Date: February 10, 2022
Renaissance Technologies LLC
By: /s/ James S. Rowen
Chief Operating Officer
Renaissance Technologies Holdings Corporation
By: /s/ James S. Rowen
Vice President
Attention: Intentional misstatements or omissions of fact constitute
Federal criminal violations (See 18 U.S.C. 1001).
Page 7 of 8 Pages
==============================================================================
EXHIBIT 99.1
AGREEMENT REGARDING JOINT FILING
UNDER RULE 13D-1(K) OF THE EXCHANGE ACT
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934,
as amended, each of the undersigned agrees to the filing on behalf of each
of a Statement on Schedule 13G, and all amendments thereto, with respect to
the shares of Common Stock, $0.001 par value of
Organovo Holdings, Inc.
Date: February 10, 2022
Renaissance Technologies LLC
By: /s/ James S. Rowen
Chief Operating Officer
Renaissance Technologies Holdings Corporation
By: /s/ James S. Rowen
Vice President
Page 8 of 8 Pages
SAN DIEGO, July 16, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that Executive Chairman Keith Murphy presented on the company's near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA. The webcast was recorded and can be viewed at https://wsw.com/webcast/jones/onvo/1848798. "The promise of FXR314 is strong and I encourage investors to review our newest presentation," said Keith Murphy, Executive Chairman. "As mergers and acquisitions continue to be str
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company's lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and preclinical models. DDW2024 is being held in Washington, D.C. May 18-21, 2024. The poster, titled, "Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel d
SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces it will be presenting data on the Company's lead clinical-stage drug, FXR314 during DDW2024, which is being held in Washington, D.C. May 18-21, 2024. The poster, titled, "Combination therapy of the FXR agonist FXR314 with tofacitinib in models of inflammatory bowel disease," will be presented on Saturday May 18, 2024 at 12:30 EDT in the session "Translational application of intestinal stem cells and organoid models." "We look forward to co
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
Aslan Pharmaceuticals Ltd (NASDAQ:ASLN)
On July 17, ASLAN Pharmaceuticals announced that its Singapore-incorporated, sole o